title: Successful surgical removal of occult metastases of medullary thyroid carcinoma recurrences with the help of immunoscintigraphy and radioimmunoguided surgery.
abstract: Patients with recurrent or metastatic medullary thyroid carcinoma (MTC) were referred for pretargeted immunoscintigraphy (Affinity Enhancement System; AES) and radioimmunoguided surgery (RIGS). Data collected from 13 patients establish that whole-body AES immunoscintigraphy revealed metastases < 360 mg and RIGS detected micrometastases (5-15 mg). All tissue samples removed by the surgeon were diagnosed by histology and immunohistochemistry of calcitonin to check the accuracy of IS and RIGS results. AES immunoscintigraphy is very sensitive. Of 34 metastases or recurrences detected, 22 had escaped physical examination or conventional imaging. The accuracy of RIGS was 86%, its sensitivity 75%, and its specificity was 90% (n = 208). IS and RIGS detected occult tumors that would have escaped surgery, clearly demonstrating clinical benefit. Serum calcitonin (normal, 10 pg/ml) and carcinoembryonic antigen (normal, 5 ng/ml) of two patients were restored to normal. In patients whose tumors were discovered, progression of their disease was slowed, as evidenced by the large decrease in serum calcitonin and carcinoembryonic antigen, an important prognostic factor. Surgery was canceled in one case where IS detected distant metastases out of surgical reach. Thus, AES immunoscintigraphy and RIGS might be of valuable help for the surgical management of medullary thyroid carcinoma.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale U.339, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: de Labriolle-Vaylet
authors.forename: P
authors.initials: P
authors.lastname: Cattan
authors.forename: E
authors.initials: E
authors.lastname: Sarfati
authors.forename: M
authors.initials: M
authors.lastname: Wioland
authors.forename: C
authors.initials: C
authors.lastname: Billotey
authors.forename: C
authors.initials: C
authors.lastname: Brochériou
authors.forename: E
authors.initials: E
authors.lastname: Rouvier
authors.forename: A
authors.initials: A
authors.lastname: de Roquancourt
authors.forename: W
authors.initials: W
authors.lastname: Rostène
authors.forename: S
authors.initials: S
authors.lastname: Askienazy
authors.forename: J
authors.initials: J
authors.lastname: Barbet
authors.forename: G
authors.initials: G
authors.lastname: Milhaud
authors.forename: A
authors.initials: A
authors.lastname: Gruaz-Guyon
mesh_terms: D000328:Adult; D000368:Aged; D002116:Calcitonin / Q000032:analysis; D002272:Carcinoembryonic Antigen / Q000097:blood; D018276:Carcinoma, Medullary / Q000000981:diagnostic imaging / Q000473:pathology / Q000556:secondary* / Q000601:surgery; D005188:False Negative Reactions; D005189:False Positive Reactions; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D016719:Radioimmunodetection; D012008:Recurrence; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery
chemical_list: D002272:Carcinoembryonic Antigen; D002116:Calcitonin